The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone ...

David A. Eichenbaum, MD, presented key data from two clinical trials focusing on therapies for age-related macular ...

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated ...

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 , 220–231 (2009). Article Google Scholar ...

Both TACE and TAE result in hypoxia, which stimulates angiogenesis, promoting tumor growth; thus combination of TACE with antiangiogenic agents may improve current results. To date, there is no ...

MMSI announces 6-month results from its WRAPSODY WAVE trial, showing superior efficacy in extending AV fistula patency for dialysis patients.

Adding bevacizumab to the combination therapy of carboplatin and paclitaxel significantly improved progression-free survival ...

Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint ...

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the ...

Choroidal neovascularization (CNV) is one of the most important vision-threatening complications secondary to pathological myopia (PM). In the last 20 years, there have been rapid advances in the ...

In 2001, I proposed a novel principle that antiangiogenic therapy can "normalize" the abnormal tumor vasculature and improve both the delivery and efficacy of therapeutics. We then provided compelling ...